Rani Therapeutics Holdings Inc (RANI) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing...

Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Qu

- Cash runway extended into 2025 - - Cash runway expected to extend beyond topline results from Phase 2 trial...

Form 8-K - Current report

Form 8-K - Current report

The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study

– Daily administration for 60 days was well-tolerated with no treatment-related adverse events – – Preclinical...

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

- RaniPill® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) - - RaniPill®...

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or...

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation...

Form 8-K - Current report

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered...

Rani Therapeutics to Participate in September Investor Conferences

SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]